Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27331946 | 0.84 | PGR (0.40) | GSK3BGRM4PGRGSR | |
| SCHEMBL27250770 | 0.84 | PDE10A (0.44) | PDE10AGSK3BFEN1PGRGSR | |
| SCHEMBL30825934 | 0.82 | PDE10A (0.53) | PDE10AGSK3BFEN1PGRGSR | |
| SCHEMBL27252120 | 0.82 | USP14 (0.42) | PDE10AGSK3BFEN1GRM4 | |
| SCHEMBL30825851 | 0.82 | USP14 (0.42) | PDE10AGSK3BFEN1GRM4 | |
| SCHEMBL8253815 | 0.78 | PDE10A (0.51) | PDE10AGSK3BFEN1PGR | |
| SCHEMBL29311787 | 0.78 | HCAR3 (0.43) | PDE10AGSK3BUSP1 | |
| SCHEMBL27253329 | 0.78 | HCAR3 (0.43) | PDE10AGSK3BUSP1 | |
| SCHEMBL29310609 | 0.77 | GSK3B (0.36) | PDE10AGSK3B | |
| SCHEMBL27446467 | 0.77 | HSD17B10 (0.35) | GSK3BGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PDE10A 1135/4885GSK3B 130/4885USP1 1875/4885 |
| US-20240217951-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | PDE10A 1137/4885GSK3B 194/4885USP1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.